Recent studies have demonstrated the effectiveness of Kleinico’s mental health diagnostic tool and Altoida’s AR-based digital cognitive and functional assessment, representing a new clinical step for the companies, as well as a hope for millions of people affected by these conditions. A newly launched global study will rely on Aktiia’s cuffless blood pressure monitoring solution.
The Klenico system is a novel diagnostic tool aiming to capture the complexity and diversity of mental disorders. It uses a comprehensive online survey covering various psychological functioning dimensions, such as emotions, cognitions, behaviours, and interpersonal relationships. The Klenico system generates a graphical representation of the patient’s profile, facilitating diagnosis and treatment planning.
To evaluate the validity and reliability of the Klenico system, Klenico conducted a large-scale study with 600 patients from outpatient and inpatient psychosomatic care and compared it with other standard diagnostic instruments, such as the Patient Health Questionnaire (PHQ), the Beck Depression Inventory-II (BDI-II), and the Yale-Brown Obsessive Compulsive Scale (Y-BOCS). The analyses show strong correlations between the majority of the disorders depicted by Klenico and the comparison instruments, proving the study’s construct validity. In addition, the Klenico disorders align with the Structured Clinical Interview for DSM-IV (SKID), the gold standard in diagnostics. These promising results illustrate that Klenico, as a valid and digital tool, can provide targeted and efficient support to professionals in the diagnosis of mental illnesses and thus contribute to evidence-based diagnoses and therapies.
Altoida AR-based digital cognitive and functional assessment
In its latest study conducted in Barcelona, Altoida found that its AR-based digital cognitive and functional assessment - in 188 MCI and healthy volunteers - provides a Digital Neuro-Signature™ (DNS-MCI) score, which correlates with standard neuropsychological tests such as the Mini-Mental State Examination (MMSE), Free and Cued Selective Reminding Test (FCSRT) and the Trail Making Test (TMT). The Swiss startup is developing digital neurological disease biomarkers using augmented reality (AR) and machine learning (ML). The Altoida digital cognitive assessment is a research device based on AR and ML that simulates conducting activities of daily living, providing an objective measure of cognitive and functional abilities in approximately 10 minutes, compared to pen-and-paper neuropsychological tests that take approximately 60-90 minutes.
Aktiia participates in landmark study
Pionieering cuffless blood pressure monitoring, Aktiia has been selected to participate in the Genetic and phenotypic determinants of blood pressure and other cardiovascular risk factors (GAPP) study, a large prospective cohort study in the Principality of Liechtenstein composed of more than 2000 participants followed for > 1 decade to determine the genetic and phenotypic factors for blood pressure and cardiovascular diseases. Aktiia's unique 24/7 Blood Pressure monitoring technology will play a key role in its ongoing research. The study aims to pave the way for more personalized, proactive, and patient-driven healthcare. This collaboration aims to unlock the links between longitudinal blood pressure patterns and genetic, biomarkers, imaging, and healthcare data, paving the way for groundbreaking discoveries in the field. Further participants include Professors David Conen MD MPH at McMaster University and Lorenz Risch MD MPH at the Private University of Liechtenstein and the Dr. Risch Laboratory.
(RAN)
0Comments
Please login or sign up to comment.
Commenting guidelines